Repros Therapeutics Inc (NASDAQ:RPRX) announced that the Division of Bone, Reproductive and Urologic Products of the U.S. Food and Drug Administration (FDA) has scheduled the advisory committee to review the Company’s New Drug Application (NDA) for its enclomiphene product candidate, formerly known as Androxal®, on November 3, 2015. The Company submitted the NDA on January 30, 2015. The FDA accepted the NDA for review on April 1, 2015 and later assigned a Prescription Drug User Fee Act (PDUFA) goal date of November 30, 2015. (Original Source)
Shares of Repros Therapeutics closed today at $7.42, up $0.21 or 2.91%. RPRX has a 1-year high of $22.55 and a 1-year low of $5.92. The stock’s 50-day moving average is $7.66 and its 200-day moving average is $8.57.
On the ratings front, Repros has been the subject of a number of recent research reports. In a report issued on May 29, Laidlaw analyst Yale Jen reiterated a Buy rating on RPRX, with a price target of $28, which represents a potential upside of 277.4% from where the stock is currently trading. Separately, on the same day, Brean Murray Carret’s Jonathan Aschoff reiterated a Buy rating on the stock and has a price target of $41.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Yale Jen and Jonathan Aschoff have a total average return of 35.0% and 10.2% respectively. Jen has a success rate of 50.0% and is ranked #727 out of 3612 analysts, while Aschoff has a success rate of 53.9% and is ranked #283.
Repros Therapeutics Inc is a development stage biopharmaceutical company. The Company is engaged in the development of new drugs to treat hormonal and reproductive system disorders.